Clinical trial
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy…
NCT00157209 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00157209 |
|---|---|
| Title | Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) |
| Official title | A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung |
| Intervention type | Biological, Drug, Other |
| Interventions | Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best Supportive Care (BSC) |
| Enrollment | 171 |
| Start date | Aug 1, 2000 |
| Primary completion | Mar 1, 2006 |
| Completion | Jul 1, 2012 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 18, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: